Eccogene GIP receptor agonist

Eccogene's GIP receptor program is a preclinical-stage development of a small molecule agonist targeting the Gastric Inhibitory Polypeptide (GIP) receptor. This oral therapeutic is being developed for the treatment of obesity and associated cardiometabolic conditions. By activating the GIP receptor, the molecule aims to modulate metabolic pathways involved in glucose homeostasis and energy expenditure. As a small molecule, it offers the potential for oral administration, distinguishing it from many existing peptide-based incretin mimetics that require injection. The program is part of Eccogene's broader metabolic pipeline, which includes other small molecule candidates targeting GLP-1 and amylin receptors.

Other names

GIP programEccogene GIP receptor small moleculeEccanga-GIP receptor-small molecule-obesity-cardiometabolic conditions